Latisse (Bimatoprost): FDA-Approved Eyelash Growth Treatment

What Is Latisse?

Latisse (bimatoprost ophthalmic solution 0.03%) is the only FDA-approved prescription treatment for hypotrichosis of the eyelashes — growing them longer, thicker, and darker.

Mechanism

Prostaglandin analog (FP receptor agonist) → prolongs anagen (growth) phase, increases number of hairs in anagen, thickens hair shaft.

Usage

• Once nightly to upper lid margin (base of lashes) using sterile applicator.
• Remove contact lenses first; wait 15 min to reinsert.
• Results: Visible at 4 weeks, full at 16 weeks.
• Maintenance: Continue nightly or reduce to 3×/week after desired effect.

Efficacy

Clinical trials: 25% length increase, 106% thickness/fullness, 18% darkness increase at 16 weeks.

Side Effects

• Common (3–4%): Conjunctival hyperemia (red eye), pruritus, dry eye, eyelid skin darkening (reversible).
• Rare: Iris pigmentation increase (brown) — permanent; more likely in hazel/green eyes. Periorbital fat atrophy (hollowed look).

Contraindications & Precautions

• Active ocular inflammation/infection (blepharitis, conjunctivitis).
• Pregnancy / breastfeeding (Category C).
• On prostaglandin analogs for glaucoma (additive IOP effect — monitor).
• History of uveitis, macular edema.

Cost & Access

~$120–180/month (insurance rarely covers cosmetic use). Compounded bimatoprost available but not FDA-approved for lashes.